Bayer Suspends Senior Staffers For Failure To Disclose Trasylol Data To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will publish findings of independent investigation, which could recommend corrective action plan.
You may also be interested in...
Bayer Revises Study Protocol Review To Prevent Another Trasylol Fiasco
Protocol Review Committee purview extended beyond prospective clinical trials based upon independent review findings.
Bayer Revises Study Protocol Review To Prevent Another Trasylol Fiasco
Protocol Review Committee purview extended beyond prospective clinical trials based upon independent review findings.
Bayer Halts Three Non-CABG Trasylol Studies
Decision to discontinue trials in certain types of cancer patients was not related to safety concerns, firm maintains.